Nuveen Asset Management LLC Has $18.72 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Nuveen Asset Management LLC lifted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 118.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 221,202 shares of the company's stock after purchasing an additional 119,780 shares during the quarter. Nuveen Asset Management LLC owned 0.46% of Axsome Therapeutics worth $18,716,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Pitcairn Co. raised its stake in shares of Axsome Therapeutics by 3.4% in the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company's stock valued at $386,000 after purchasing an additional 148 shares in the last quarter. Meridian Wealth Management LLC grew its position in Axsome Therapeutics by 0.7% in the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock valued at $1,791,000 after acquiring an additional 150 shares during the period. Summit Investment Advisors Inc. grew its position in Axsome Therapeutics by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company's stock valued at $326,000 after acquiring an additional 162 shares during the period. Arizona State Retirement System grew its position in Axsome Therapeutics by 1.8% in the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock valued at $766,000 after acquiring an additional 164 shares during the period. Finally, Intrust Bank NA grew its position in Axsome Therapeutics by 6.9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company's stock valued at $239,000 after acquiring an additional 183 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 3,000 shares of the stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $107.49, for a total value of $322,470.00. Following the transaction, the director now owns 54,137 shares of the company's stock, valued at approximately $5,819,186.13. This represents a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 22.30% of the company's stock.

Axsome Therapeutics Trading Down 1.0%

Axsome Therapeutics stock traded down $1.09 during mid-day trading on Tuesday, hitting $103.98. The stock had a trading volume of 441,549 shares, compared to its average volume of 688,230. The stock has a 50-day simple moving average of $108.44 and a two-hundred day simple moving average of $106.00. The stock has a market capitalization of $5.12 billion, a PE ratio of -17.36 and a beta of 0.46. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AXSM shares. Deutsche Bank Aktiengesellschaft started coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price target on the stock. Morgan Stanley upped their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Royal Bank of Canada upped their price target on Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a research report on Tuesday, April 29th. Bank of America increased their target price on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Finally, Leerink Partners increased their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $172.14.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.